According to a recent market study published by Growth Market Reports, titled, “Global Patient Derived Xenograft (PDX) Models Market by Type, by Tumor Type, by Application, by End-user, and by Region: Size, Share, Trends and Opportunity Analysis, 2017-2027”, the market was valued at US$ 113.5 Million in 2019 and is expected to grow at a healthy growth rate of 14.5% by the year 2027. Patient-derived xenografts (PDX) are models of cancer in which the cells from a patient’s tumor are inserted into an immune deficient or humanized mouse. PDX models simulate that human tumor biology is allowing for natural cancer progression and offers translational research for calculating the desired result. Patient-derived xenograft (PDX) mouse models includes the insertion of fresh human tumor samples directly into the immune-deficient mice by surgery. Xenograft animal models are required for testing the effectiveness of medicines and are mostly required in drug advancement for cancer, diabetes, infections, etc.

The global patient derived xenograft (PDX) models market is fragmented based on types, tumor types, applications, end-user, and region. Based on the types, the market is bifurcated into mice models and rat models. In terms of tumor types, the market is categorized as gastrointestinal tumor models, gynecological tumor models, respiratory tumor models, urological tumor models, hematological tumor models, and others. On the basis of applications, the market is segmented into preclinical drug development, biomarker analysis, and basic cancer research. In terms of end-user, the market is segregated into pharmaceutical & biotechnology companies, contract research organizations (CROs), and academic & research institutions. Based on region the global patient derived xenograft (PDX) models market has been fragmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa.

Request a free sample copy @ https://growthmarketreports.com/request-sample/2512

The patient derived xenograft (PDX) models market is expected to witness a decrease its in year-on-year growth for 2020 as compared to for previous year 2019. Interruption in the supply chain of patient derived xenograft (PDX) models across the globe due to the spread of COVID-19 has a moderate negative impact on the product sales. Thus, the import and export of patient derived xenograft (PDX) models has witnessed a small decline in sales across the world in 2020. Low availability of resources towards COVID-19 related testing, treatment, and clinical research affected the stalling of clinical trials for different therapeutic areas. Almost 61% of clinical trials were stalled, due to suspension of patient enrolment. Moreover, inadequate raw material supply and lack of available workforce for production of patient derived xenograft (PDX) models in the first and second quadrant of 2020 had hampered the market growth in 2020.

As per Growth Market Reports industry analyst Akshata Ahire, “The global patient derived xenograft (PDX) models market is anticipated to witness significant growth during forecast period 2020-2027. Gene expression in tumors is maintained by sequential path of tumors from mouse to mouse. These models support research for tumor pharmacology & biology deprived of manual influence of cell cultures and are usually used in modified cancer therapy, drug enlargement and clinical tests. PDX models show advanced predictive values for clinical results than cell linederived xenograft models and hereditarily engineered mouse models. This, in turn, is projected to create ample of opportunities for this market in coming years.”

Key Takeaways from the Study:

  • The players including Abnova Corporation, Aragen Bioscience, a GVKBIO Company, Bioduro, Champions Oncology, Inc., Charles River Laboratories, Envigo, EPO Berlin-Buch GmbH, Explora BioLabs, Hera, Biolabs, NexusPharma, Oncodesign, THE JACKSON LABORATORY, Urosphere, WuXi AppTec, and Xentech, together hold major market share of global patient derived xenograft (PDX) models market in year 2019.
  • Asia Pacific is a promising region for the market. The market in this region is expected to grow in the coming years owing to the growth in the healthcare industry and increasing import of PDX models.
  • In terms of value, the basic cancer research segment accounted for substantial share of the market in 2019 and the preclinical drug development segment is expected to expand at a substantial CAGR during the forecast period.
  • In terms of value, the respiratory tumor models segment held significant share of the market in 2019, and is projected to expand at a considerable CAGR during the forecast period, owing to increasing incidences of lung cancer globally.

Report Scope:

Report Metric

Details

Market Value in 2019

US$ 113.5 Million

Market Growth Rate (from 2020 to 2027)

14.5%

Historical Data

2017, & 2018

Base Year

2019

Forecast Period

2020 - 2027

Units Considered

Value (US$ Million)

Market Segments

By Types, By Tumor Types, By Applications, By End-user, and Region

Regional Scope

North America, Europe, Asia Pacific, Latin America, Middle East & Africa

Key Companies Profiled

Abnova Corporation
Aragen Bioscience, a GVKBIO Company
Bioduro
Champions Oncology, Inc.
Charles River Laboratories
Envigo
EPO Berlin-Buch GmbH
Explora BioLabs
Hera Biolabs
NexusPharma
Oncodesign
THE JACKSON LABORATORY
Urosphere
WuXi AppTec
Xentech

Customization Scope

Report customization available on request

Pricing and Purchase Options

Avail tailor-made purchase options to meet your research requirements.

Target Audience:

  • Supply-side: Manufacturers, raw material suppliers, and distributors
  • Demand Side: Food Industry, Biofuel Industry, and Cosmetics Industry
  • Regulatory Side: Concerned government authorities, and other regulatory bodies
  • Associations and Industry Bodies: Food and Drug Administration (FDA), American Association for Cancer Research (AAACR), Association for Assessment and Accreditation of Laboratory Animal Care (AAALAC), Biotechnology Regional Innovation Centers (BRICs), Technology Innovation Agency (TIA), Australian Competition and Consumer Commission (ACCC), and Others